What are the recommended management guidelines for an adult patient with chronic hepatitis C infection?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Hepatitis C Positive Patients

All adults with chronic hepatitis C should be treated with direct-acting antiviral (DAA) therapy, with regimen selection based on HCV genotype, presence of cirrhosis, and treatment history. 1, 2

Initial Assessment

Diagnostic Testing

  • Confirm active infection with HCV RNA testing (not just antibody)
  • Determine HCV genotype (1-6) as this guides treatment selection
  • Assess for cirrhosis using FIB-4 score:
    • FIB-4 >3.25 suggests cirrhosis
    • Consider transient elastography (FibroScan >12.5 kPa) or other non-invasive markers
    • Liver biopsy is NOT required 2
  • Screen for hepatitis B (HBsAg) and HIV
  • Baseline labs: CBC, comprehensive metabolic panel, HCV RNA quantitative

Pre-Treatment Considerations

  • Medication reconciliation for drug-drug interactions (critical with DAAs)
  • Pregnancy status in women of reproductive age
  • Renal function (eGFR) as some regimens require adjustment

Treatment Regimens by Genotype

Genotype 1 (Most Common in US)

Treatment-Naïve Patients Without Cirrhosis:

  • Glecaprevir/pibrentasvir: 8 weeks (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1
  • Ledipasvir/sofosbuvir: 12 weeks (can shorten to 8 weeks if HCV RNA <6 million IU/mL) (A1) 1

Treatment-Naïve Patients With Compensated Cirrhosis:

  • Glecaprevir/pibrentasvir: 12 weeks (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1
  • Ledipasvir/sofosbuvir: 12 weeks (A1) 1

Treatment-Experienced Patients:

  • Ledipasvir/sofosbuvir + ribavirin: 12 weeks OR ledipasvir/sofosbuvir alone for 24 weeks (A1) 1
  • Glecaprevir/pibrentasvir: 8 weeks (no cirrhosis) or 12 weeks (cirrhosis) (A1) 1

Genotype 2

Treatment-Naïve Without Cirrhosis:

  • Glecaprevir/pibrentasvir: 8 weeks (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1
  • Sofosbuvir + ribavirin: 12 weeks (A1) 1, 3

Treatment-Naïve With Cirrhosis:

  • Glecaprevir/pibrentasvir: 12 weeks (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1
  • Sofosbuvir + ribavirin: 16 weeks (B1) 1

Genotype 3 (More Difficult to Treat)

Treatment-Naïve Without Cirrhosis:

  • Glecaprevir/pibrentasvir: 8 weeks (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1

Treatment-Naïve With Cirrhosis:

  • Glecaprevir/pibrentasvir: 12 weeks (B1) 1
  • Sofosbuvir/velpatasvir + ribavirin: 12 weeks (A1) 1
  • Sofosbuvir/velpatasvir/voxilaprevir: 8 weeks (A1) 1

Treatment-Experienced:

  • Glecaprevir/pibrentasvir: 16 weeks (B1) 1
  • Sofosbuvir/velpatasvir + ribavirin: 12 weeks (A1) 1

Genotype 4

Treatment-Naïve:

  • Glecaprevir/pibrentasvir: 8 weeks (no cirrhosis) or 12 weeks (cirrhosis) (A1) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1
  • Ledipasvir/sofosbuvir: 12 weeks (A1) 1

Genotypes 5 & 6

Treatment-Naïve:

  • Ledipasvir/sofosbuvir: 12 weeks (A1) 1, 3
  • Sofosbuvir/velpatasvir: 12 weeks (A1) 1

Simplified Treatment Approach

For treatment-naïve adults without cirrhosis (FIB-4 ≤3.25), the following pan-genotypic regimens can be used with minimal monitoring 2:

  • Glecaprevir/pibrentasvir: 8 weeks (taken with food)
  • Sofosbuvir/velpatasvir: 12 weeks

This simplified approach is NOT appropriate for:

  • Prior HCV treatment failure
  • Cirrhosis (see specific recommendations above)
  • eGFR <30 mL/min
  • HIV or HBV coinfection
  • Pregnancy
  • Hepatocellular carcinoma
  • Prior liver transplant

On-Treatment Monitoring

Minimal monitoring is required for most patients:

  • No routine laboratory monitoring needed for uncomplicated cases 2
  • Warn patients on diabetes medications about potential hypoglycemia
  • Monitor INR in patients on warfarin (risk of subtherapeutic anticoagulation)
  • Optional telehealth/phone check-in for adherence support

Post-Treatment Assessment

Sustained Virologic Response (SVR) = Cure:

  • Check HCV RNA at 12 weeks after completing therapy (SVR12)
  • Undetectable HCV RNA = virologic cure (>95% success rate with modern DAAs)

Post-SVR Management:

Without Cirrhosis:

  • No liver-related follow-up required 4
  • Counsel on reinfection prevention (especially in people who inject drugs)

With Compensated Cirrhosis:

  • Continue HCC surveillance: Abdominal ultrasound ± AFP every 6 months indefinitely 4
  • Variceal screening: Upper endoscopy every 2-3 years 4
  • Cirrhosis does NOT resolve with HCV cure, though fibrosis may regress over time

Special Populations

Pregnancy

  • Screen all pregnant women during each pregnancy 2, 5
  • Defer treatment until after delivery (DAAs not approved in pregnancy)
  • Test exposed infants with HCV RNA at 2-6 months of age (new 2023 recommendation) 6

Children

  • Adolescents 12-17 years: Treat as adults with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir 7
  • Children 3-11 years: Weight-based dosing of sofosbuvir/velpatasvir available 7

Renal Impairment

  • eGFR ≥30: Most regimens safe
  • eGFR <30 or dialysis: Use glecaprevir/pibrentasvir (avoid sofosbuvir-based regimens)

Critical Pitfalls to Avoid

  1. Don't delay treatment waiting for advanced fibrosis—treat all patients regardless of fibrosis stage
  2. Don't use interferon-based regimens—DAAs are superior in efficacy and tolerability
  3. Don't forget drug-drug interaction screening—DAAs have significant interactions (especially with proton pump inhibitors, anticonvulsants, and HIV medications)
  4. Don't stop HCC surveillance in cirrhotic patients after SVR—cancer risk persists
  5. Don't assume antibody-positive = active infection—always confirm with HCV RNA
  6. Don't use genotype 1a regimens for genotype 3—genotype 3 requires specific approaches

References

4
Research

Hepatitis C: Diagnosis and Management.

American family physician, 2021

5
Research

CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020.

MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports, 2020

Related Questions

What is the appropriate treatment plan, including medication dosages, for a patient with hepatitis C?
What is the risk of acquiring hepatitis C after accidental exposure to blood from a hepatitis C patient, given that I have two open cuts on my hand and performed hand washing?
Should chronic hepatitis C be treated in a critically ill patient?
In a 32-year-old patient with a history of intravenous drug use and hepatitis C who presents with new-onset edema and a low‑normal ejection fraction (50‑55%) on an otherwise normal echocardiogram, what laboratory tests should be ordered?
Can a person be infected with hepatitis C more than once?
What short‑term measures can be used to minimize lumbar facet joint stress and low‑back pain in patients with pre‑existing spinopelvic malalignment when placed in the lithotomy position?
What is the appropriate ICD‑10 code for an episode of hypoglycemia?
What is the appropriate outpatient evaluation and management plan for a 32-year-old woman with no past medical history who experiences episodes of sinus bradycardia with heart rates in the 30s?
Can a proton-pump inhibitor be given with anti-tuberculosis therapy to reduce emesis?
Can a normal urinalysis be consistent with a urinary tract infection if the urine culture is positive?
What is the recommended management for a 19‑month‑old with acute otitis media that has not improved after initial antibiotic therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.